Pharmaceutical Executive Digest Europe - February 25, 2009 - (Page 3) News (continued from page 2) sciences and healthcare sectors. Andrew Kay, Algeta’ CEO, said, “The fact that we have been able to raise USD 35 million in the present economic climate demonstrates investors’ confidence in Algeta’s ability to generate shareholder value via the successful development and commercialisation of our lead product, Alpharadin.” Alpharadin is a next-generation alpha- pharmaceutical (alpha-emitting pharmaceutical) based on radium-223 and which is in a phase III clinical trial as a potential new treatment for bone metastases in patients with hormone-refractory prostate cancer (HRPC). Action boss wins Novo Nordisk prize Søren Nielsen, CEO of Danish biotech company Action Pharma, has won the 2009 Novo Nordisk Prize. The annual prize is in recognition of unique medical research or other research contributions that are of benefit to medical science, and is awarded for a predominantly Danish contribution. The award is based on Mr Nielsen and colleagues’ discoveries concerning the fundamental role of cell membrane water channels (aquaporins) in water balance regulation, and the pivotal roles they play in water balance disorders, such as acquired and inherited kidney diseases, heart failure and brain edema. The work was performed in collaboration with Professor Peter Agre of Johns Hopkins University Medical School, who received the 2003 Nobel Prize in Chemistry for the discovery of aquaporin water channels. Action Pharma has two drug candidates in late preclinical development and several discovery projects under way. 1 9 NEWS BIOFUTURES 2 11 FROM THE EDITOR / NEWS DIGITAL MARKETING 6 CALENDAR 7 JACKY LAW 13 ON THE MOVE SUBSCRIBE TO PHARM EXEC http://www.actionpharma.com http://www.kendle.com http://www.kendle.com http://www.pharmexeceurope.com/europharmexec/newsletter/subscribeNewsletter.jsp
Table of Contents Feed for the Digital Edition of Pharmaceutical Executive Digest Europe - February 25, 2009 Pharmaceutical Executive Digest Europe - February 25, 2009 Contents From the Editor News Calendar Critical Vision Biofutures Digital Marketing On the Move Pharmaceutical Executive Digest Europe - February 25, 2009 Pharmaceutical Executive Digest Europe - February 25, 2009 - Contents (Page 1) Pharmaceutical Executive Digest Europe - February 25, 2009 - News (Page 2) Pharmaceutical Executive Digest Europe - February 25, 2009 - News (Page 3) Pharmaceutical Executive Digest Europe - February 25, 2009 - News (Page 4) Pharmaceutical Executive Digest Europe - February 25, 2009 - News (Page 5) Pharmaceutical Executive Digest Europe - February 25, 2009 - Calendar (Page 6) Pharmaceutical Executive Digest Europe - February 25, 2009 - Critical Vision (Page 7) Pharmaceutical Executive Digest Europe - February 25, 2009 - Critical Vision (Page 8) Pharmaceutical Executive Digest Europe - February 25, 2009 - Biofutures (Page 9) Pharmaceutical Executive Digest Europe - February 25, 2009 - Biofutures (Page 10) Pharmaceutical Executive Digest Europe - February 25, 2009 - Digital Marketing (Page 11) Pharmaceutical Executive Digest Europe - February 25, 2009 - Digital Marketing (Page 12) Pharmaceutical Executive Digest Europe - February 25, 2009 - On the Move (Page 13)
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.